Photodynamic therapy with oral administration of 5-aminolevulinic acid for the treatment of skin cancers and hair follicle sebaceous glands tumors

Photodynamic therapy with oral administration of 5-aminolevulinic acid for the treatment of skin cancers and hair follicle sebaceous glands tumors - Photodynamic therapy with oral administration of 5-aminolevulinic acid for the treatment of skin cancers and hair follicle sebaceous glands tumors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007523

Enrollment

Registered

2012-03-21

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin cancers and hair follicle sebaceous glands tumors

Interventions

Oral administration of 5-aminolevulinic acid two hour before therapy.And the lesions will be irradiated with Dye laser(10J/cm2).The treatment will be done once a month for three months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who gave their written informed consent

Exclusion criteria

Exclusion criteria: Patients who meet any of the conditions described below are excluded. 1. Patients with hypersensitivity to 5-ALA or porphyrins. 2. In case of known or suspected pregnancy, or women who are breast-feeding. 3.In case of known or suspected acute or chronic types of porphyria. 4. In case of renal insufficiency (serum creatinine is more than 2.0mg/dl) 5. In case of hepatic insufficiency (serum gamma glutamyl transpeptidase >100IU/l, ptotronbin time <60% or total bilirubin >3mg/dl) 6. In case of other conditions considered as undesirable for entry in this clinical trial.

Design outcomes

Primary

Measure	Time frame
The efficacy of photodynamic therapy with oral administration of 5-aminolevulinic acid	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026